NASDAQ: ELOXEloxx Pharmaceuticals Inc Stock
$12.81+0.70 (+5.78%)
Updated Jul 28, 2026
ELOX Price
$12.81
Fair Value Price
$3.38
Market Cap
$15.22M
52 Week Low
$0.00
52 Week High
$17.50
P/E
N/A
P/B
-2.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-2.12
Operating Cash Flow
N/A
Beta
-114.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ELOX Overview
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELOX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ELOX
Ranked#86 of 460
Ranked#86 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $256.92 | A | |
| $11.24 | A | |
| $8.24 | A |
Be the first to know about important ELOX news, forecast changes, insider trades & much more!
ELOX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELOX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELOX ($12.81) is overvalued by 279.26% relative to our estimate of its Fair Value price of $3.38 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELOX ($12.81) is not significantly undervalued (279.26%) relative to our estimate of its Fair Value price of $3.38 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELOX's short-term liabilities ($16.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more ELOX due diligence checks available for Premium users.
Valuation
ELOX fair value
Fair Value of ELOX stock based on Discounted Cash Flow (DCF)
Price
$12.81
Fair Value
$3.38
Overvalued by
279.26%
ELOX ($12.81) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELOX ($12.81) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELOX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
23.44x
Market
14.6x
ELOX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.01x
Industry
5.4x
ELOX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
Assets to liabilities
Assets
$8.5M
Liabilities
$16.1M
Debt to equity
-2.12
ELOX's short-term liabilities ($16.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELOX's short-term assets ($8.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELOX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELOX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.5M
Investing
$0.0
Financing
$7.0M
ELOX vs Biotech Stocks
Eloxx Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.